Table 4 Univariate analyses of clinical-pathological parameters for the prediction of cancer-specific survival, locoregional control and recurrence-free survival in patients treated with definitive radio (chemo/immuno-) therapy

Sex

 Male

1

1

1

 Female

1.30 (0.69–2.45)

1.14 (0.64–2.04)

1.11 (0.63–1.94)

Age at diagnosis

 < 60

1

1

1

 > 60

0.76 (0.44–1.32)

0.78(0.48–1.28)

0.72 (0.45–1.15)

Smoking status

 Former or never

1

1

1

 Current

2.36 (1.21–4.61)

2.11 (1.19–3.73)

2.18 (1.26–3.78)

Alcohol consumption

 Former or never

1

1

1

 Current

1.72 (0.98–3.02)

1.65 (0.99–2.74)

1.59 (0.98–2.58)

Tumor grade

 G 1/2

1

1

1

 G 3/4

0.87 (0.49–1.53)

0.87 (0.53–1.42)

0.82 (0.51–1.32)

Tumor stage

 T 1/2

1

1

1

 T 3/4

1.79 (0.65–4.98)

2.273(0.83–6.26)

1.57 (0.68–3.64)

Nodal involvement

 N0

1

1

1

 N+

1.75 (0.63–4.87)

1.54 (0.66–3.59))

1.72 (0.74–3.99)

Induction chemotherapy

 Yes

1

1

1

 No

0.80 (0.44–1.45)

0.79 (0.47–1.34)

0.93 (0.57–1.53)

Concomitant chemotherapy

 Yes

1

1

1

 No

0.63 (0.29–1.34)

0.72 (0.35–1.45)

0.68 (0.35–1.34)

Chemo-/Immunotherapy

 No

1

1

1

 Erbitux

1.14 (0.48–2.68)

1.02 (0.45–2.32)

0.97 (0.44–2.13)

 Cisplatin

0.51 (0.23–1.11)

0.64 (0.31–1.32)

0.61 (0.35–1.22)

RTx technique

 3D conformal

1

1

1

 IMRT

0.75 (0.42–1.33)

0.89 (0.53–1.49)

0.93 (0.57–1.53)

RTx total dose (Gy)

 ≤ 60

1

1

1

 > 60 to < 70

1.51 (0.29–7.90)

1.57 (0.30–8.19)

2.69 (0.64–11.43)

 ≥ 70

0.51 (0.20–1.30)

0.61(0.24–1.53)

0.66 (0.26–1.65)

Platelet count (G/L)

 Median (mean ± SD)

1.003 (1.000–1.006)

1.004 (1.001–1.006)

1.003 (1.001–1.006)

MPV (fL)

 Median (mean ± SD)

0.68 (0.50–0.91)

0.77 (0.59–0.99)

0.77(0.60–0.99)